Xinxin Chen , Xiaohan Jiang , Bo Zhang , Zhiqiang Liu , Yuguo Zheng
{"title":"Rerouting of phytosterol degradation pathways in targeted high-yield and high-purity 9α-hydroxyandrost-4-ene-3,17-dione microbial biotransformation","authors":"Xinxin Chen , Xiaohan Jiang , Bo Zhang , Zhiqiang Liu , Yuguo Zheng","doi":"10.1016/j.bej.2025.109723","DOIUrl":null,"url":null,"abstract":"<div><div>9α-Hydroxyandrost-4-ene-3,17-dione (9-OHAD) is a representative precursor in steroid drug synthesis. However, during the 9-OHAD production from phytosterol in <em>Mycolicibacterium neoaurum</em> (<em>M. neoaurum</em>), the current manufacturing processes suffer from low productivity and purity due to the generation of a variety of by-products. In this study, we genetically modified the phytosterol catabolism <em>in M. neoaurum</em> and achieved 13.4 g/L and 91.1 % molar yield of 9-OHAD with no detectable by-products at a high phytosterol concentration of 20 g/L in shake flask. It was achieved by inactivating <em>Opccr</em>, <em>SalA</em>, <em>TeB</em>, and overexpressing <em>KshA1</em> and <em>ChsH1–2</em> to eliminate the production of 20-hydroxymethyl-9,21-dihydroxy-20-methyl-pregna-4-en-3-one (9-OH-4-HBC), 4-androstene-3,17-dione (4-AD) and 3-oxo-4-pregnene-9-OH-20-carboxylic methyl ester (9-OH-3-OPCM) as well as overcoming the production limitations of 9-OHAD. Notably, when scaled up in a 5 L bioreactor with 45 g/L phytosterol concentration, the modified <em>M. neoaurum</em> achieved 24.5 g/L and 74.5 % molar conversion of 9-OHAD by using soybean oil and (2-hydroxypropyl)-β-cyclodextrin (HP-β-CD) as a co-solvent and antifoam agent. Therefore, our findings demonstrate a method to improve the efficiency and purity of 9-OHAD biosynthesis in <em>M. neoaurum</em>.</div></div>","PeriodicalId":8766,"journal":{"name":"Biochemical Engineering Journal","volume":"219 ","pages":"Article 109723"},"PeriodicalIF":3.7000,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical Engineering Journal","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1369703X2500097X","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
9α-Hydroxyandrost-4-ene-3,17-dione (9-OHAD) is a representative precursor in steroid drug synthesis. However, during the 9-OHAD production from phytosterol in Mycolicibacterium neoaurum (M. neoaurum), the current manufacturing processes suffer from low productivity and purity due to the generation of a variety of by-products. In this study, we genetically modified the phytosterol catabolism in M. neoaurum and achieved 13.4 g/L and 91.1 % molar yield of 9-OHAD with no detectable by-products at a high phytosterol concentration of 20 g/L in shake flask. It was achieved by inactivating Opccr, SalA, TeB, and overexpressing KshA1 and ChsH1–2 to eliminate the production of 20-hydroxymethyl-9,21-dihydroxy-20-methyl-pregna-4-en-3-one (9-OH-4-HBC), 4-androstene-3,17-dione (4-AD) and 3-oxo-4-pregnene-9-OH-20-carboxylic methyl ester (9-OH-3-OPCM) as well as overcoming the production limitations of 9-OHAD. Notably, when scaled up in a 5 L bioreactor with 45 g/L phytosterol concentration, the modified M. neoaurum achieved 24.5 g/L and 74.5 % molar conversion of 9-OHAD by using soybean oil and (2-hydroxypropyl)-β-cyclodextrin (HP-β-CD) as a co-solvent and antifoam agent. Therefore, our findings demonstrate a method to improve the efficiency and purity of 9-OHAD biosynthesis in M. neoaurum.
期刊介绍:
The Biochemical Engineering Journal aims to promote progress in the crucial chemical engineering aspects of the development of biological processes associated with everything from raw materials preparation to product recovery relevant to industries as diverse as medical/healthcare, industrial biotechnology, and environmental biotechnology.
The Journal welcomes full length original research papers, short communications, and review papers* in the following research fields:
Biocatalysis (enzyme or microbial) and biotransformations, including immobilized biocatalyst preparation and kinetics
Biosensors and Biodevices including biofabrication and novel fuel cell development
Bioseparations including scale-up and protein refolding/renaturation
Environmental Bioengineering including bioconversion, bioremediation, and microbial fuel cells
Bioreactor Systems including characterization, optimization and scale-up
Bioresources and Biorefinery Engineering including biomass conversion, biofuels, bioenergy, and optimization
Industrial Biotechnology including specialty chemicals, platform chemicals and neutraceuticals
Biomaterials and Tissue Engineering including bioartificial organs, cell encapsulation, and controlled release
Cell Culture Engineering (plant, animal or insect cells) including viral vectors, monoclonal antibodies, recombinant proteins, vaccines, and secondary metabolites
Cell Therapies and Stem Cells including pluripotent, mesenchymal and hematopoietic stem cells; immunotherapies; tissue-specific differentiation; and cryopreservation
Metabolic Engineering, Systems and Synthetic Biology including OMICS, bioinformatics, in silico biology, and metabolic flux analysis
Protein Engineering including enzyme engineering and directed evolution.